Neoadjuvant treatment in advanced resectable melanoma and the need for a predictive biomarker - is pathologic complete response (pCR) the answer?
- 1University of Michigan, Department of Medicine, Division of Medical Oncology, Ann Arbor, MI, USA.
- 2University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; University of Michigan Department of Surgery, Division of Surgical Oncology, Ann Arbor, MI, USA; University of Michigan Department of Dermatology, Ann Arbor, MI, USA.
- 3University of Michigan, Department of Medicine, Division of Medical Oncology, Ann Arbor, MI, USA; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
- 0University of Michigan, Department of Medicine, Division of Medical Oncology, Ann Arbor, MI, USA.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.

